Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI(r) (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

PRINCETON: BRISTOL MYERS SQUIBB has issued the following news release: Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for [...]